BACKGROUND: A psychological disorder poses a greater risk of all-cause of deaths at earlier stages of life1. According to epidemiological research, people with mental illnesses have a 7 to 24 year lower life expectancy, which is a bigger toll than heavy smoking. METHODOLOGY: The study had comprised of n=140 individuals who had mental problems and were deficient in both vitamin D and vitamin E. All individuals had been taking antipsychotic drugs on a consistent basis for at least two months previous to the commencement of the research, and their antipsychotic doses remained constant throughout the study. RESULTS: The analyses of the findings had revealed that participants in the Risperidone group had substantially higher levels of Total Cholesterol after antidepressant administration (235.26±35.37 vs. 157.09±16.34 mg/dL; p<0.0001). When compared to other treatment groups, the mean value of Total Cholesterol was considerably lower (p<0.05) in the group receiving Quetiapine coupled with Vitamin E and Vitamin D. Regarding efficacy, the treatment groups receiving Olanzapine, Risperidone, Quetiapine, Olanzapine combined with Vitamin E and Vitamin D, and Risperidone combined with Vitamin E and Vitamin D did not show any significant effects on the Total Cholesterol levels of patients (208.06±34.32 vs. 229.31±37.59 vs. 178.86±25.23 vs. 178.11±20.72 mg/dL, respectively). CONCLUSION: In conclusion, the study's findings demonstrated that risperidone usage was related with higher levels of total cholesterol and lower levels of high-density lipoprotein (HDL) compared to the control group. When quetiapine was coupled with vitamins E and D, total cholesterol and low-density lipoprotein (LDL) levels were significantly reduced. Furthermore, when individuals in the risperidone group were given with vitamin E and vitamin D, their triglyceride levels were lower.